Helixmith is a gene therapy company based in Seoul, Korea and San Diego, CA, developing new and innovative biopharmaceuticals to tackle previously untreated diseases. The company has an extensive gene therapy pipeline. VM202, the most advanced pipeline candidate, is a plasmid DNA therapy in phase III clinical trials for painful diabetic peripheral neuropathy. VM202 is also being studied for diabetic foot ulcers, claudication, ALS, coronary artery disease, and Charcot-Marie-Tooth disease.
Brands: Helixmith is actively recruiting for subjects in a painful diabetic peripheral neuropathy trial for VM202, our plasmid DNA product.